Promise for combination approach to cancer
4-1BB, cancer, immuno-oncology, immunotherapy, Keytruda, Oncology, Opdivo, PD-1, R&D, T-cell
0 Comment
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.